BR112023026249A2 - Direcionamento seletivo de células alorreativas cd70+ do hospedeiro para prolongar a persistência de células t car alogênicas - Google Patents

Direcionamento seletivo de células alorreativas cd70+ do hospedeiro para prolongar a persistência de células t car alogênicas

Info

Publication number
BR112023026249A2
BR112023026249A2 BR112023026249A BR112023026249A BR112023026249A2 BR 112023026249 A2 BR112023026249 A2 BR 112023026249A2 BR 112023026249 A BR112023026249 A BR 112023026249A BR 112023026249 A BR112023026249 A BR 112023026249A BR 112023026249 A2 BR112023026249 A2 BR 112023026249A2
Authority
BR
Brazil
Prior art keywords
cells
car
persistence
prolong
engineered
Prior art date
Application number
BR112023026249A
Other languages
English (en)
Portuguese (pt)
Inventor
Johnson Sasu Barbra
Adolfo Sommer Cesar
J Lauron Elvin
Shanshan Lang
Siler Panowski
Srivatsa Srinivasan Surabhi
John Van Blarcom Thomas
Original Assignee
Allogene Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allogene Therapeutics Inc filed Critical Allogene Therapeutics Inc
Publication of BR112023026249A2 publication Critical patent/BR112023026249A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4232—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
BR112023026249A 2021-06-15 2022-06-15 Direcionamento seletivo de células alorreativas cd70+ do hospedeiro para prolongar a persistência de células t car alogênicas BR112023026249A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163210979P 2021-06-15 2021-06-15
US202263351223P 2022-06-10 2022-06-10
PCT/US2022/033598 WO2022266203A1 (en) 2021-06-15 2022-06-15 Selective targeting of host cd70+ alloreactive cells to prolong allogeneic car t cell persistence

Publications (1)

Publication Number Publication Date
BR112023026249A2 true BR112023026249A2 (pt) 2024-03-05

Family

ID=82608367

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023026249A BR112023026249A2 (pt) 2021-06-15 2022-06-15 Direcionamento seletivo de células alorreativas cd70+ do hospedeiro para prolongar a persistência de células t car alogênicas

Country Status (10)

Country Link
US (4) US20220409665A1 (https=)
EP (1) EP4355358A1 (https=)
JP (1) JP2024526090A (https=)
KR (1) KR20240021826A (https=)
AU (1) AU2022292640A1 (https=)
BR (1) BR112023026249A2 (https=)
CA (1) CA3221957A1 (https=)
IL (1) IL308468A (https=)
MX (1) MX2023014866A (https=)
WO (1) WO2022266203A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202440623A (zh) 2022-11-28 2024-10-16 美商艾洛基因醫療公司 靶向密連蛋白１８﹒２之嵌合抗原受體及結合劑以及其用途
WO2025096594A2 (en) * 2023-10-30 2025-05-08 Allogene Therapeutics, Inc. Cells expressing anti-cd19 chimeric antigen receptors and methods of use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
BR112014029417B1 (pt) 2012-05-25 2023-03-07 Cellectis Método ex vivo para a preparação de células t para imunoterapia
BR112017013981A2 (pt) 2015-01-26 2018-01-02 Cellectis receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
WO2019099479A1 (en) * 2017-11-14 2019-05-23 Memorial Sloan-Kettering Cancer Center Il-33 secreting immunoresponsive cells and uses thereof
CN112020518A (zh) * 2018-02-01 2020-12-01 辉瑞公司 靶向cd70的嵌合抗原受体
EP4031150A4 (en) * 2019-09-16 2023-11-01 The General Hospital Corporation CD70-DIRECTED CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS AND USES THEREOF
WO2022129216A1 (en) * 2020-12-15 2022-06-23 Universiteit Antwerpen Cell-based therapeutics targeting cd70

Also Published As

Publication number Publication date
US20260116989A1 (en) 2026-04-30
AU2022292640A1 (en) 2023-11-30
AU2022292640A9 (en) 2023-12-14
IL308468A (en) 2024-01-01
JP2024526090A (ja) 2024-07-17
CA3221957A1 (en) 2022-12-22
US20260109771A1 (en) 2026-04-23
WO2022266203A1 (en) 2022-12-22
EP4355358A1 (en) 2024-04-24
MX2023014866A (es) 2024-01-16
US20220409665A1 (en) 2022-12-29
US20260042857A1 (en) 2026-02-12
KR20240021826A (ko) 2024-02-19

Similar Documents

Publication Publication Date Title
US20230081443A1 (en) Anti-il1rap antibodies
BR112022012524A2 (pt) Porção química de ligação que se liga especificamente a claudin18.2, polinucleotídeo, vetor, célula hospedeira, receptor de antígeno quimérico (car ), célula imune geneticamente modificada, composição farmacêutica, método de tratamento de um tumor ou câncer que expressa claudin18.2
AU2016265845B2 (en) Chimeric antigen receptor compositions
AU2020248448B2 (en) Chimeric antigen receptor modified T-cells (CAR-T) for the treatment of hematological and solid tumor cancers
JP2020531515A (ja) 癌治療向け免疫療法とサイトカイン制御療法の組合せ
BR112019022972A2 (pt) Fomulações estáveis de anticorpos de receptor de morte programada 1 (pd-1) e métodos de uso das mesmas
BR112018070676A2 (pt) construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos
BR112023026249A2 (pt) Direcionamento seletivo de células alorreativas cd70+ do hospedeiro para prolongar a persistência de células t car alogênicas
BR112022025989A2 (pt) Moléculas, um ou mais polinucleotídeos, um ou mais vetores, célula hospedeira, método para produzir uma molécula, composição farmacêutica, uso da molécula e método para tratar uma doença
JP7734661B2 (ja) 抗ｒｏｒ－２抗体および使用方法
Martínez et al. Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a phase II study
BR112022014264A2 (pt) Composições e métodos para aumentar ou melhorar a transdução de vetores de terapia genética e para remover ou reduzir imunoglobulinas
BR112022026429A2 (pt) Anticorpo anti-cd2 recombinante, sequência de ácido nucleico, formulação farmacêutica, método para tratar um distúrbio crônico do sistema imune, método para manter tolerância imune a um transplante em um receptor de transplante e método para tratar ou prevenir um distúrbio ou uma doença imune
JP2021530444A (ja) 固形および液体悪性病変における多重ｃａｒ ｔ細胞での複数抗原の標的化
Hu et al. A promising sword of tomorrow: human γδ T cell strategies reconcile allo-HSCT complications
KR20200041377A (ko) Strep-tag 특이적 결합 단백질 및 그 용도
MX2023011788A (es) Anticuerpos contra ilt4, anticuerpo biespecifico anti-ilt4/pd-l1 y usos de los mismos.
BR112022026999A2 (pt) Anticorpos anti-il-36r para tratamento de dermatoses neutrofílicas
JP2025038083A (ja) 癌関連免疫抑制阻害剤
BR112022014501A2 (pt) Métodos para dosagem e tratamento de linfoma folicular e linfoma de zona marginal em terapia celular adotiva
Gross et al. An Hsp70 peptide initiates NK cell killing of leukemic blasts after stem cell transplantation
US20260008864A1 (en) Bispecific anti-cd38-cd3 binders
BR112023011658A2 (pt) Anticorpo de domínio único anti-gucy2c (sdab), receptor de antígeno quimérico (car), ácido nucleico isolado, vetor, célula efetora imune manipulada, composição farmacêutica e método de tratamento de uma doença ou distúrbio em um sujeito
Steinbach et al. Clinical application of dendritic cells and interleukin-2 and tools to study activated T cells in horses—First results and implications for quality control
BR112023018987A2 (pt) Receptores de antígenos quiméricos direcionados à claudina-3 e métodos de tratamento do câncer